Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)

Ischemic Stroke Clinical Trial

Official title:

A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Multicenter, Blind, Randomized, Placebo Controlled Single Injection of It-hMSC in Patients With Ischemic Stroke

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04590118
• Other study ID #: STCMSC-CT-001
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: April 26, 2021
• Est. completion date: August 1, 2023

Study information

• Verified date: March 2022
• Source: Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of single injection of it-hMSC in patients with ischemic stroke in a multicenter, blind, randomized, placebo controlled trial

Description:

Stroke is a leading cause of disability. According to the comprehensive standardized prevalence estimation in 2016, 12.42 million people older than 40 years in China are currently suffering from stroke or have ever suffered from stroke. The overall prevalence rate of stroke in China was 1,596 per 100,000 people in 2016, 4.6 times higher than the rate of 345.1 per 100,000 people in 2013 and 70% of the survivors have disabilities in varying degrees. In addition to rehabilitation therapy, there is no therapeutic drugs of remarkable curative effect for the treatment of ischemic stroke patients. The latest data show that the annual recurrence rate of ischemic stroke in China is as high as 17.7%.

Allogeneic mesenchymal stem cells have been used in many clinical studies for different diseases. In addition to differentiating into multiple cell types and promoting the recovery and repair of the brain by replacing damaged cells, mesenchymal stem cells also secrete cytokines and neurotrophic factors to support and stimulate the growth of other endogenous cells. Meanwhile, mesenchymal stem cells also have anti-inflammatory and immunomodulatory functions. These characteristics of mesenchymal stem cells provide a new therapy for the treatment of stroke.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: August 1, 2023
• Est. primary completion date: April 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years or older.

• Clinical diagnosis of ischemic stroke for more than 6 months.

• Imaging findings suggestive of ischemic stroke with functional deficits at initial diagnosis and enrollment.

• Severe neurological impairment associated with the diagnosis of ischemic stroke that resulted in the subject needing assistance to walk or not being able to perform general daily activities independently.

• No substantial improvement in neurologic or functional deficits for the 2 months prior to enrollment.

• NIHSS score between 6-20.

• Life expectancy longer than 12 months.

• Prior to treatment, the patient received standard medical care for secondary prevention of ischemic stroke, including but not limited to appropriate blood pressure and cholesterol control measures, use of antiplatelet agents or anticoagulants (except when prohibited).

• Understand and provide signed informed consent, or have a designated legal guardian or spouse make such decision voluntarily on behalf of the subject.

• Expected that the patient will receive standard medical care for secondary prevention of ischemic stroke and participate in all planned safe follow-up visits reasonably.

• Organ function as defined by the following criteria:

AST = 2.5×ULN ALT = 2.5×ULN TSB =1.5×ULN PT =1.25×ULN and PTT =1.25×ULN in subjects who did not receive antithrombotic therapy Serum albumin = 3.0g/dL ANC = 1,500/µL Platelets = 150,000/µL Hemoglobin = 9.0g/dL Serum creatinine = 1.5×ULN Serum amylase or lipase = 1.0×ULN

Exclusion Criteria:

• History of epilepsy.

• History of cancer.

• History of brain trauma and brain tumor.

• Positive for hepatitis B surface antigen, E antigen, E antibody, core antibody, hepatitis C, HIV or RPR.

• Myocardial infarction occurred within six months of study entry.

• Any other medical problems of clinical significance, abnormal mental or test results that the investigator or sponsor determined participating in the study pose a safety risk to the subject.

• Imaging findings suggestive of subarachnoid hemorrhage or intracerebral hemorrhage in the past 12 months.

• Participation in any study of experimental drug or device within 3 months.

• Participation in other study related to stem cell-therapy.

• History of drug or alcohol abuse within 1 year.

• Pregnant, lactating or planning to become pregnant during the trial.

• Allergic to cattle or pork products.

Related Conditions & MeSH terms

• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Drug:
• it-hMSC
Single intravenous infusion of it-hMSC for ischemic stroke patients
• Placebo
Single intravenous infusion of 1 ml/kg placebo

Locations

Country	Name	City	State
China	Beijing Tiantan Hospital, Capital Medical University	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.	Beijing Tiantan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and severity of adverse events assessed by CTCAE V5.0 during the twelve-month study period after it-hMSC infusion.		12 months
Secondary	Modified Rankin Scale	The change from the baseline in Modified Rankin Scale will be calculated at month 1, month 3, month 6, month 9, month 12 post-treatment, as available.; The scale is divided into 7 degrees, from 0 (no deficit) to 6 (dead).	month 1, month 3, month 6, month 9, month 12
Secondary	National Institute of Health stroke scale	The change from the baseline in National Institute of Health stroke scale will be calculated at month 1, month 3, month 6, month 9, month 12 post-treatment, as available.; The range of scores is from 0 (normal) to 42.	month 1, month 3, month 6, month 9, month 12
Secondary	Mini-mental State Examination	The change from the baseline in Mini-mental State Examination will be calculated at month 1, month 3, month 6, month 9, month 12 post-treatment, as available.; The range of scores is from 0 to 30 (normal).	month 1, month 3, month 6, month 9, month 12
Secondary	Barthel Index	The change from the baseline in Barthel Index will be calculated at month 1, month 3, month 6, month 9, month 12 post-treatment, as available.; The range of scores is from 0 to 100 (normal).	month 1, month 3, month 6, month 9, month 12
Secondary	Geriatric Depression Scale	The change from the baseline in Geriatric Depression Scale will be calculated at month 1, month 3, month 6, month 9, month 12 post-treatment, as available.; The range of scores is from 0 (normal) to 10.	month 1, month 3, month 6, month 9, month 12